




**SOCIETÀ CHIMICA ITALIANA**  
*Gruppo Interdivisionale "Chimica dei Carboidrati"*

# **ATTI XIII CONVEGNO-SCUOLA SULLA CHIMICA DEI CARBOIDRATI**

**24-27 Giugno 2012**  
*Certosa di Pontignano - Siena*



Università di Pisa  
*Dipartimento Scienze Farmaceutiche*



Università degli Studi di Siena  
*Dipartimento Farmaco Chimico e Tecnologico*



Università degli Studi di Firenze  
*Dipartimento Chimica "U. Shiff"*

## A 2,3-CARBAMATE-BEARING ALLYL GALACTOSAMINE DONOR FOR THE SYNTHESIS OF REPEATING $\alpha$ -(1 $\rightarrow$ 4)-LINKED GALACTOSAMINE UNITS

Maria Vetro,<sup>[a]</sup> Laura Legnani,<sup>[b]</sup> Lucio Toma,<sup>[b]</sup> Fiamma Ronchetti,<sup>[a]</sup>  
Federica Compostella<sup>[a]</sup>

[a] *Università di Milano, Dip. Chimica, Biochimica e Biotecnologie per la Medicina,  
via Saldini 50, 20133 Milano*

[b] *Università di Pavia, Dip. Chimica, via Taramelli 10, 27100 Pavia*

The 1,2-*cis*-linked 2-amino-2-deoxy sugar structure is found in various oligosaccharides of biological importance. The repeating GalpNAc- $\alpha$ -(1 $\rightarrow$ 4)-GalpNAc unit constitutes for example an essential motif incorporated in a range of oligosaccharides, e.g. the repeating unit of the O-antigen moiety of the lipopolysaccharide from *Escherichia Coli* O142 or *Sphaerotilus natans*.<sup>[1]</sup> Vi antigen is instead a linear homopolymer of  $\alpha$ -(1 $\rightarrow$ 4)-linked N-acetyl galactosaminuronic monomers, with a variable degree of O-acetylation at the C3 position. Vi antigen is a capsular polysaccharide found mainly in *Salmonella typhi* and *Salmonella paratyphi C*, two serotypes of *Salmonella* that are responsible for severe infection in humans.<sup>[2]</sup>

Although in the past years there has been much progress in carbohydrate chemistry, 1,2-*cis*-selective glycosylation of gluco- or galactosamines is still a challenge. 2-Azidoglycosyl donors, developed many years ago, are still employed for the synthesis of 2-amino-2-deoxy  $\alpha$ -glycosides, even if glycosylations suffer of low selectivity. Progress in resolving these issues has been made with the development of donors carrying a 2,3-*trans*-carbamate group, which has attracted much attention as a stereodirecting protection in glycosylation reactions. The fused carbamate ring proved to be a non-participating group and favors the formation of  $\alpha$ -glycosides. So far, different studies have demonstrated that 2,3-oxazolidinone protected thioglycosides are highly efficient substrates for the synthesis of  $\alpha$ -linked glycosides.<sup>[3]</sup> Herein we report a new 2,3-oxazolidinone protected galactosamine donor, bearing an allyl group at the anomeric position. The allyl group, in addition to its traditional role as a valuable anomeric protecting group, can also be converted into a good leaving group for glycosylation. Thus, the allyl glycoside is first isomerized to the corresponding prop-1-enyl glycoside, which, after chemoselective activation of the anomeric enol ether moiety with a suitable electrophile in the presence of the glycosyl acceptor, leads to the formation of the disaccharide product.<sup>[4]</sup> This method has the advantage that prop-1-enyl glycoside can be directly derived from allyl glycoside with a variety of facile and highly effective isomerization methods and immediately subjected to glycosylation.

Herein we describe the synthesis of a galactosamine building block, which has the anomeric position protected by an allyl group, and positions 2 and 3 involved in the formation of an oxazolidinone ring. The proper donor and acceptor to perform a  $\alpha$ -(1 $\rightarrow$ 4) glycosylation have been obtained from this common building block. The new 2,3-oxazolidinone protected allyl galactosamine donor has been subjected to glycosylation reactions to study its reactivity and the stereoselectivity of the process.

1. a) Landersjö, C.; Widmalm, G. *Biopolymers* **2002**, *64*, 283; b) Takeda, M.; Nakamori, T.; Hatta, M.; Yamada, H.; Koizumi, J.I. *Int. J. Biol. Macromol.* **2003**, *33*, 245
2. a) Daniels, E.M.; Schneerson, R.; Egan, W.M.; Szu, S.C.; Robbins, J.B. *Infect. Immun.* **1989**, *57*, 31592; b) Heyns, K.; Kiessling, G. *Carbohydr. Res.* **1967**, *3*, 340

3. See for examples: a) Kerns R.J., Zha C., Benakli K., Liang Y.Z, *Tetrahedron Lett.* **2003**, *44*, 8069; b) Olsson, J. D. M.; Eriksson, L.; Lahmann, M.; Oscarson, S. *J. Org. Chem.* **2008**, *73*, 7181; c) Yang, L.; Ye, X-S. *Carbohydr. Res.* **2010**, *345*, 1713; d) Yang, L.; Zhu, J. ; Zheng, X-J. ; Tai, G. ; Ye, X-S. *Chem. Eur. J.* **2011**, *17*, 14518
4. Wang, Y.; Zhang, X.; Wang, P. *Org. Biomol. Chem.* **2010**, *8*, 4322 and references herein reported.

We acknowledge MIUR-Italy (PRIN 2008) for financial support.